Company / Capital Expenditures
Verrica Pharmaceuticals Inc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$27.0K
FY2025
5-year range
$27.0K / $1.5M
FY2021-FY2025
Trend
-92.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $302,000 to $27,000 over the past 2 years.
Based on SEC 10-K filings.
$27,000 in FY2025 with a 3-year CAGR of -68.7%.
Declined from $302,000 to $27,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -68.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -68.7%, indicating a declining trend.
- In FY2025, capital expenditures decreased 92.5% year-over-year.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.0K | -92.5% |
| FY2024 | $362.0K | +19.9% |
| FY2023 | $302.0K | -65.8% |
| FY2022 | $883.0K | -39.9% |
| FY2021 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026